CAREERS

3 Biotech Companies Ramping Up Hiring After Closing $275 Million in Combined Series C Funding in 2026

MyDigiFolio Editors 3 min read
Biotechnology scientists and computational biologists collaborating in a modern pharmaceutical research laboratory.
Biotechnology scientists and computational biologists collaborating in a modern pharmaceutical research laboratory.

Three late-stage biotechnology firms—Triveni Bio, Ratio Therapeutics, and Basecamp Research—are actively expanding their scientific, clinical, and engineering headcounts after securing a combined $275 million in Series C financing during 2026. Backing clinical trials in immunology, targeted oncology radiopharmaceuticals, and AI-driven gene-editing platforms, the fresh capital is fueling active recruitment across Massachusetts, Utah, and London. For biopharma professionals navigating a selective job market, well-capitalized Series C companies offer near-term clinical momentum and commercial sca

As biopharma job seekers target resilient employers capable of weathering tighter venture markets, companies that have closed later-stage Series C financing stand out for their clinical validation and operational runway. Three high-growth biotechnology developers—Triveni Bio, Ratio Therapeutics, and Basecamp Research—raised a combined $275 million between June and September 2026 and are actively recruiting across research, clinical operations, manufacturing, and AI engineering.

1. Triveni Bio: $65 Million Series C Headquartered in Watertown, Massachusetts, Triveni Bio develops genetics-informed antibody therapies targeting primary disease drivers in immunological and inflammatory disorders such as atopic dermatitis, asthma, and eosinophilic esophagitis.

  • Pipeline & Clinical Momentum: Following its $65 million Series C raise in June 2026, Triveni completed enrollment in a Phase 2 proof-of-concept trial for its lead half-life extended monoclonal antibody, TRIV-509 (with topline data expected by year-end 2026), dosed its first Phase 2 patient for next-generation bispecific TRIV-573, and transferred pancreatitis candidate TRIV-920 to a rare-disease biopharma partner. CEO Vishal Patel was also named a finalist for the Ernst & Young Entrepreneur Of The Year 2026 award.

  • Open Roles: Recruiting in Watertown for positions including Senior Scientist (Clinical Pharmacology), Director of Medical Writing, and Senior Scientist (Translational Research).

2. Ratio Therapeutics: $70 Million Series C Boston-based Ratio Therapeutics engineers targeted radiopharmaceuticals for oncology using its proprietary Trillium and Macropa platforms, which harness alpha-emitting actinium-225 to selectively destroy tumor cells.

  • Pipeline & Pharma Partnerships: Backed by a $70 million Series C closed in July 2026, Ratio is advancing its lead candidate [Ac-225]RTX-2358 in the ATLAS Phase 1/2 trial for relapsed or treatment-resistant soft tissue sarcoma while scaling manufacturing capacity. The company also maintains strategic partnerships with Novartis (therapeutics) as well as Lantheus and Merck (diagnostics).

  • Open Roles: Hiring a Scientist/Senior Scientist (Radiopharma Development and Tech Transfer) and Facilities Engineer in West Valley City, Utah, alongside a Chemistry Laboratory Operations Associate in Boston.

3. Basecamp Research: $140 Million Series C Operating out of London with offices and laboratories in Cambridge, Massachusetts, Basecamp Research combines frontier biological AI models trained on proprietary biodiversity data with programmable DNA-writing technology.

  • AI Foundation Models & Gene Insertion: Powered by its biological foundation model EDEN, Basecamp designs synthetic large serine recombinases (LSRs) capable of inserting healthy gene copies upstream of disease-causing mutations across oncology, autoimmunity, and diabetes. Its $140 million Series C closed in September 2026 will train next-generation EDEN models, advance AI-designed therapeutics toward the clinic, and expand pharma collaborations.

We believe the future of medicine lies in reprogramming the body to repair itself. We design the models and the medicines to teach it how." — Glen Gowers, Co-Founder & CEO, Basecamp Research

Open Roles: Recruiting for nearly a dozen roles across both hubs, including Senior Research Scientist (AI Safety and Biosecurity) in London, and Software Engineer (Science Platform) and Scientist (Peptide Discovery) in Boston.

From MyDigiFolio

Reading about careers? Build yours.

One profile. Resume, vCard, portfolio, and email signatures — all generated in 3 minutes.

Build your page — free

The Brief, in your inbox

Five must-reads.
Every Monday.

A curated digest of the week's biggest career, AI, and business stories. With our take. No spam.

Or subscribe via RSS · Protected by reCAPTCHA

We use essential cookies for login and preferences, and optional cookies for analytics. Privacy policy.